We are using ethical and representative AI technology to pioneer groundbreaking health ventures that transform health journeys, empowering communities in the global south.
Our cutting-edge technology can address complex healthcare challenges and make a meaningful impact on people's lives.
Products, services, technology
EmpathicAI builds ethical AI solutions for healthcare. Our portfolio includes LakeSAI, a membership-based research agent that supports drug development with AI-driven insights, and Xaidi, a digital assistant for neurodivergent individuals and caregivers.
Cooperation possibilities
We want to connect with biotech companies, research teams, translational medicine units and innovation leaders who are exploring AI in their drug development. We also welcome partners from academia and funding agencies interested in data-driven health innovation.
- http://empathicAI.life
- +41 79 610 14 19
- Send an email
- Martin Dober
Some insights
We build ethical AI tools that improve access to healthcare, especially in underrepresented and resource-constrained settings. Our solutions combine empathy and science to support real people in real life.
We are proud about what we do, because we are proving that AI can be both ethical and impactful. Our work brings healthcare support to people who are often overlooked, combining cutting-edge science with a human-centered approach that puts empathy first.
We are proud to have worked with Trevor Mundel at the Gates Foundation, who champions equitable global health.
EmpathicAI is a venture builder with deep expertise in AI, life sciences and public health. Our team includes PhDs and alumni of Roche/Genentech, Novartis, AstraZeneca and McKinsey. We aim to add clinical and regulatory skills to scale ethical, impactful digital health solutions.
My daugthers would say I talk to computers all day trying to make them care about people.
By connecting us with Swiss biotech companies open to using our LakeSAI platform in their drug development process. Early adoption and feedback from real projects would help us prove its value and continuously refine it for the needs of the Swiss biotech ecosystem.
We want to connect with biotech companies, research teams, translational medicine units and innovation leaders who are exploring AI in their drug development. We also welcome partners from academia and funding agencies interested in data-driven health innovation.